Please assess the completion status of the following clinical trial:

Trial Title: Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria for patients who may develop acute graft versus host disease:~* All patients undergoing an allogeneic hematopoietic stem cell transplant at CCHMC.~* All conditioning regimens are eligible.~Exclusion criteria for patients who may develop acute graft versus host disease:~• Pre-existing skin conditions like, but not limited to epidermolysis bullosa, psoriasis, acne, or cellulitis.~Inclusion criteria for patients who have chronic graft versus host disease:~* Bone marrow transplant performed at CCHMC or an outside institution.~* Diagnosis of chronic skin graft versus host disease.~Exclusion criteria for patients who have chronic graft versus host disease:~• Bone marrow transplant performed for epidermolysis bullosa.~Inclusion criteria for controls:~* Healthy volunteers.~* Age matched to the patients with existing acute skin graft versus host disease.~Exclusion criteria for controls:~• Pre-existing dermatologic conditions. (E.g. eczema, psoriasis, acne etc.)

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Acute Graft versus Host Disease (Type: EXPERIMENTAL): This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop acute graft versus host disease. Skin cell samples will be collected using the D-SQUAME Skin Sampling Discs. The first baseline skin sample will be obtained prior to the preparative regimen for stem cell transplant. Samples will be collected weekly after stem cell infusion until 8 weeks, if acute GVHD does not develop. If acute GVHD does develop, weekly samples will continue to be collected until resolution of acute GVHD or development of chronic GVHD, whichever occurs first. Blood samples will be collected at these same time points.
- Chronic Graft versus Host Disease (Type: EXPERIMENTAL): This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop chronic graft versus host disease. Skin cell samples will be collected weekly for 4 weeks using the D-SQUAME Skin Sampling Discs. Blood samples will be collected at these same time points.
- Healthy Controls (Type: ACTIVE_COMPARATOR): This study arm includes healthy age matched controls as comparisons to study participants who develop graft versus host disease. These controls may be either healthy age matched siblings of patients who develop acute graft versus host disease or healthy age matched siblings of patients that are seen in the bone marrow transplant, oncology, or hematology clinics. A one-time single skin cell sample will be collected using a D-SQUAME Skin Sampling Disc. Blood samples will not be collected from the healthy controls.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete